Clinical trial
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine…
NCT00037869 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00037869 |
|---|---|
| Title | High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors |
| Official title | High Dose I-131 Metaiodobenzylguanidine (MIBG) Therapy for Metastatic Neuroendocrine Tumors |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumors, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | I-131 Metaiodobenzylguanidine |
| Enrollment | 15 |
| Start date | Nov 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | May 27, 2002 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: